Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HINT1 | P49773 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.30 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279160 | 1.00 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL22702575 | 1.00 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL17231771 | 1.00 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL19519229 | 0.91 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL19775596 | 0.91 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL20650242 | 0.89 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL17283049 | 0.88 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL7202323 | 0.86 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL16609224 | 0.85 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL30012820 | 0.85 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4286519-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3137479-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180016294-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016293-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-01-18 | — | — | US | disclosed |
| US-9796747-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-11-26 | — | — | US | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | KDM4E 4575/4885TAS1R3 4567/4885TAS1R1 4757/4885 |
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | KDM4E 4575/4885TAS1R3 4567/4885TAS1R1 4757/4885 |
| US-20180016293-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | KDM4E 4575/4885TAS1R3 4567/4885TAS1R1 4757/4885 |
| US-20180016294-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | KDM4E 4575/4885TAS1R3 4567/4885TAS1R1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.